Paper34482769
Hepatitis D virus (HDV): investigational therapeutic agents in clinical trials.
Asif B and 1 other. Expert Opin Investig Drugs, 2022. Cited by 6 papers, by iCite.
Cite this record
ConductScience Library. Hepatitis D virus (HDV): investigational therapeutic agents in clinical trials. Papers, record 34482769. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/34482769
- Sources
- 11 sources
- Release
- papers-2026-11-12-0.1.0
Paper
PubMed's record of the paper, with iCite's citation figures. No abstract is shown.
Topics7
NLM's MeSH indexing of the paper, its major topics first.
| MeSH term | Major |
|---|---|
| Carcinoma, Hepatocellular | Major topic |
| Hepatitis D | Major topic |
| Hepatitis D, Chronic | Major topic |
| Liver Neoplasms | Major topic |
| Hepatitis B virus | |
| Hepatitis Delta Virus | |
| Humans |
Source PubMed
Grants2
Each grant PubMed's record writes, matched to the NIH project NIH's grant and paper links name for this paper, and each of those links the record does not write.
| Grant, as the record writes it | Agency | Country | NIH project | Stated by | Source |
|---|---|---|---|---|---|
| Z99 DK999999 | Intramural NIH HHS | United States | Z99DK999999 | PubMed | NIH RePORTER |
| ZIA DK075150 | Intramural NIH HHS | United States | ZIADK075150 | PubMed | NIH RePORTER |
Trials1
The trials whose ClinicalTrials.gov record lists the paper, and the trial numbers the paper's PubMed record names.
| Trial | Title | The trial lists it as | Named in the paper's record |
|---|---|---|---|
| NCT03852433 | Study to Assess Efficacy and Safety of Bulevirtide in Combination With Pegylated Interferon Alfa-2a in Participants With Chronic Hepatitis Delta (CHD) | Background |
Source ClinicalTrials.gov
References114
The papers the reference list in PubMed's record names, those in our copy of PubMed, in the list's order.
| Order | PMID | Title | Journal | Year | In Papers | Source |
|---|---|---|---|---|---|---|
| 1 | 8116240 | Isoprenylation of large hepatitis delta antigen is necessary but not sufficient for hepatitis delta virus assembly. | Virology | 1994 | https://conductscience.org/library/papers/8116240 | PubMed |
| 2 | 16495266 | Potent antiscrapie activities of degenerate phosphorothioate oligonucleotides. | Antimicrob Agents Chemother | 2006 | https://conductscience.org/library/papers/16495266 | PubMed |
| 3 | 26897654 | Pathogenesis by subviral agents: viroids and hepatitis delta virus. | Curr Opin Virol | 2016 | https://conductscience.org/library/papers/26897654 | PubMed |
| 4 | 2481341 | Mechanisms of action of interferons. | Semin Liver Dis | 1989 | https://conductscience.org/library/papers/2481341 | PubMed |
| 5 | 8617711 | The hepatitis delta virus large antigen is farnesylated both in vitro and in animal cells. | J Biol Chem | 1996 | https://conductscience.org/library/papers/8617711 | PubMed |
| 6 | 15613342 | Roles of carboxyl-terminal and farnesylated residues in the functions of the large hepatitis delta antigen. | J Virol | 2005 | https://conductscience.org/library/papers/15613342 | PubMed |
| 7 | 16959288 | The human RNA polymerase II interacts with the terminal stem-loop regions of the hepatitis delta virus RNA genome. | Virology | 2007 | https://conductscience.org/library/papers/16959288 | PubMed |
| 8 | 32398799 | Modelling hepatitis D virus RNA and HBsAg dynamics during nucleic acid polymer monotherapy suggest rapid turnover of HBsAg. | Sci Rep | 2020 | https://conductscience.org/library/papers/32398799 | PubMed |
| 9 | 27880976 | A novel quantitative microarray antibody capture assay identifies an extremely high hepatitis delta virus prevalence among hepatitis B virus-infected mongolians. | Hepatology | 2017 | https://conductscience.org/library/papers/27880976 | PubMed |
| 10 | 25098971 | Understanding early serum hepatitis D virus and hepatitis B surface antigen kinetics during pegylated interferon-alpha therapy via mathematical modeling. | Hepatology | 2014 | https://conductscience.org/library/papers/25098971 | PubMed |
| 11 | 3794405 | Titration of the infectivity of hepatitis D virus in chimpanzees. | J Infect Dis | 1987 | https://conductscience.org/library/papers/3794405 | PubMed |
| 12 | 33099752 | Ropeginterferon alfa-2b every 2 weeks as a novel pegylated interferon for patients with chronic hepatitis B. | Hepatol Int | 2020 | https://conductscience.org/library/papers/33099752 | PubMed |
| 13 | 30562970 | A Divergent Hepatitis D-Like Agent in Birds. | Viruses | 2018 | https://conductscience.org/library/papers/30562970 | PubMed |
| 14 | 16443667 | Identification of human liver cytochrome P450 enzymes responsible for the metabolism of lonafarnib (Sarasar). | Drug Metab Dispos | 2006 | https://conductscience.org/library/papers/16443667 | PubMed |
| 15 | 6934539 | delta Agent: association of delta antigen with hepatitis B surface antigen and RNA in serum of delta-infected chimpanzees. | Proc Natl Acad Sci U S A | 1980 | https://conductscience.org/library/papers/6934539 | PubMed |
| 16 | 30833068 | Peginterferon alfa-2a plus tenofovir disoproxil fumarate for hepatitis D (HIDIT-II): a randomised, placebo controlled, phase 2 trial. | Lancet Infect Dis | 2019 | https://conductscience.org/library/papers/30833068 | PubMed |
| 17 | 22932972 | Treatment of chronic delta hepatitis. | Semin Liver Dis | 2012 | https://conductscience.org/library/papers/22932972 | PubMed |
| 18 | 3762705 | Structure, sequence and expression of the hepatitis delta (delta) viral genome. | Nature | 1986 | https://conductscience.org/library/papers/3762705 | PubMed |
| 19 | 21268724 | Peginterferon plus adefovir versus either drug alone for hepatitis delta. | N Engl J Med | 2011 | https://conductscience.org/library/papers/21268724 | PubMed |
| 20 | 30228220 | Prevalence and burden of hepatitis D virus infection in the global population: a systematic review and meta-analysis. | Gut | 2019 | https://conductscience.org/library/papers/30228220 | PubMed |
Cited by7
The papers in our copy of PubMed whose reference list names this one, newest first. iCite, which reads more sources, counts 6 citations.
| PMID | Title | Journal | Year | In Papers | Source |
|---|---|---|---|---|---|
| 42875707 | The Economic Burden of HDV in Italy: Evaluating the Potential Impact and Effects of Bulevirtide for Chronic HDV Infection. | Clin Drug Investig | 2026 | https://conductscience.org/library/papers/42875707 | PubMed |
| 42828159 | Therapeutic, preventive, and pathogenetic advances in viral hepatitis. | Front Cell Infect Microbiol | 2026 | https://conductscience.org/library/papers/42828159 | PubMed |
| 40006617 | Clinical Pharmacology of Bulevirtide: Focus on Known and Potential Drug-Drug Interactions. | Pharmaceutics | 2025 | https://conductscience.org/library/papers/40006617 | PubMed |
| 36712949 | Bulevirtide in the Treatment of Hepatitis Delta: Drug Discovery, Clinical Development and Place in Therapy. | Drug Des Devel Ther | 2023 | https://conductscience.org/library/papers/36712949 | PubMed |
| 36621853 | Diagnosis of HDV: From virology to non-invasive markers of fibrosis. | Liver Int | 2023 | https://conductscience.org/library/papers/36621853 | PubMed |
| 36519386 | Epidemiology, presentation, and therapeutic approaches for hepatitis D infections. | Expert Rev Anti Infect Ther | 2023 | https://conductscience.org/library/papers/36519386 | PubMed |
| 35632728 | Hepatitis B Virus-Associated Hepatocellular Carcinoma. | Viruses | 2022 | https://conductscience.org/library/papers/35632728 | PubMed |
Data dates
The date of each source this release read.
- Trials
- 2026-11-12
- Gene search
- 2026-11-11
- Pipelines
- 2026-09-18
None in this release
- Comments and corrections
- Genes
- Drugs
- Data
Sources 11
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- HGNCCC0
- iCiteCC BY 4.0
- NCBI GenePublic domain (US government)
- NIH RePORTER's grant and paper linksPublic domain
- Open TargetsCC0 1.0
- PMC's ID filePublic domain (US government)
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- HGNCCC0: https://www.genenames.org/about/license/
- iCiteCC BY 4.0
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this paper from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/papers/v1/34482769
GET https://conductscience.org/api/papers/v1/34482769/references?page=2